Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CX1440 capsules in adults with persistent or chronic immune thrombocytopenia
ChiCTR2400093926Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bangsaitinib in immune thrombocytopenia (ITP) (3 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Proportion of subjects achieving platelet count >=50 x10^9/L during treatment. Started Dec 2024; status: completed.
02
Drugs
bangsaitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400093926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093926.